Two Phase 1 trials, one in the US and the other in Japan, have been completed and are currently in extension phase with 7 patients remaining under treatment.
“Taletrectinib (AB106/DS6051b) demonstrated meaningful clinical activity in advanced ROS1+NSCLC patients who are ROS1 TKI-naive or crizotinib-refractory and a manageable safety profile.”
– Sai-Hong Ignatius Ou, M.D., Ph.D.
Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA, USA
For questions about ongoing clinical trials, please contact email@example.com